Top Democrat sounds 'alarm bells' over Obama rhetoric on Islamic State

J&J to submit at least 10 medicines for approval by 2019

By Bill Berkrot and Caroline Humer NEW YORK (Reuters) – U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines. J&J said it would file for approval of the experimental drug daratumumab for the blood cancer multiple myeloma

Novo Nordisk rejects Baxter patent claim over Novoeight

Novo Nordisk said on Wednesday it rejected claims by U.S. rival Baxter International that it had infringed patents on drugs to treat the bleeding disorder hemophilia, the Danish company said on Wednesday. Baxter had said Novo Nordisk’s newly launched hemophilia drug Novoeight infringed some of its patents, prompting an investigation from the U.S. International Trade Commision announced on Monday. “Novo Nordisk strongly disagrees and has asked the court to intervene